HONG KONG, Aug. 10, 2026 /PRNewswire/ -- Akeso, Inc. (9926.HK) ("Akeso" or the "Company") announced that the first patient has been dosed in a Phase II clinical study (AK146D1-202) evaluating AK146D1, the Company's internally developed TROP2/Nectin-4 bispecific antibody-drug conjugate...
Hence then, the article about akeso advances io2 0 adc2 0 strategy first patient dosed in phase ii study of trop2 nectin 4 bispecific adc ak146d1 combined with ivonescimab in breast cancer was published today ( ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.
Read More Details
Finally We wish PressBee provided you with enough information of ( Akeso Advances IO2.0 + ADC2.0 Strategy: First Patient Dosed in Phase II Study of TROP2/Nectin-4 Bispecific ADC (AK146D1) Combined with Ivonescimab in Breast Cancer )
Also on site :
- Pentagon awards Raytheon $20.7 billion AMRAAM contract
- 1979 Beloved Hit by The Police, Which Topped UK Charts 47 Years Ago Today, Surprisingly Flopped in the U.S.
- Walmart’s Enchanting Tree Trunk Lamp Set Adds Dreamy Folklore Vibes and Instant Storybook Charm to Your Home